Search Clinical Trials

Clinical Trials Search Results

The results of your search are listed below. To view the details of a trial or study, click on the see details >> link. Or start a new search.

Searched for: Acute Myeloid Leukemia (AML)

37 results total

A Feasibility Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients with Advanced AML or High Risk Myelodysplastic Syndrome

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: 1809.00

Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study

See details >>

Principal Investigator: Monica Thakar, MD

Study Number: 2064.00

Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza?) in Combination with Gemtuzumab Ozogamicin (Mylotarg?) as Induction and Post-Remission Therapy in Older Patients with Previously Untreated Non-M3 Acute Myeloid Leukemia

See details >>

Principal Investigator: Roland Walter, MD

Study Number: 2200.00

A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

See details >>

Principal Investigator: Marie Bleakley, MD

Study Number: 2222.00

Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

See details >>

Principal Investigator: Merav Bar, MD

Study Number: 2272.00

A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)

See details >>

Principal Investigator: Roland Walter, MD

Study Number: 2288.00

A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: 2302.00

Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias (AML)

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: 2315.00

Dose Escalation Study of Clofarabine in Combination with Cytarabine (ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients

See details >>

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 6562

A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation oand Subsequent Randomization to Post Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 56 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)

See details >>

Principal Investigator: Stephen Petersdorf, MD

Study Number: SWOG 0106

Displaying first 10 of 37 total results. Click to view all 37 results.

Search Options

Select a disease from the list below:

Limit results to studies enrolling:
Both Adults & Pediatrics Adults Pediatrics

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.